Sturchio, Andrea
Dwivedi, Alok K.
Gastaldi, Matteo
Grimberg, Maria Barbara
Businaro, Pietro
Duque, Kevin R.
Vizcarra, Joaquin A.
Abdelghany, Elhusseini
Balint, Bettina
Marsili, Luca
Espay, Alberto J. http://orcid.org/0000-0002-3389-136X
Article History
Received: 25 October 2021
Accepted: 6 December 2021
First Online: 13 January 2022
Declarations
:
: MBG, PB, KRD, JAV, EA, NW, and BB have nothing to report. AS is cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies. AKD is supported as a co-investigator by the NIH (1 R21 HL143030-01) and (R21 AI133207) grants. He is also currently serving as a statistician in CPRIT funded studies (PP200006, PP190058, PP180003, and PP170068). MG has received honoraria from Roche. LM has received honoraria from the International Association of Parkinsonism and Related Disorders (IAPRD) Society. He serves on the Editorial board of the Journal of Clinical Movement Disorders. AJE: has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, Kyowa Kirin, Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Acadia, and Sunovion. He serves on the editorial boards of the Journal of Parkinson’s Disease, European Journal of Neurology, and JAMA Neurology. He is cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies.
: Not required.
: Not required.
Free to read: This content has been made available to all.